DeepMed Research

Adavosertib

Generic Name: Adavosertib

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₂N_₈O_₂

CAS Number: 955365-80-7

Unique Ingredient Identifier: K2T6HJX3I3

Background: MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Clinical Trials

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Fallopian Tube Carcinoma

Interventions: Drug: Adavosertib
Drug: Olaparib
Drug: Ceralasertib

First Posted Date: 2018-07-06

Last Posted Date: 2025-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 96

Registration Number: NCT03579316

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Savolitinib
Drug: Darolutamide
Drug: Durvalumab and Tremelimumab
Drug: CFI-400945
Drug: Adavosertib
Drug: Ipatasertib
Drug: Carboplatin

First Posted Date: 2017-12-28

Last Posted Date: 2025-03-17

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 200

Registration Number: NCT03385655

Locations: 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 8 locations

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Phase 1

Terminated

Conditions: Cervical Carcinoma
Endometrioid Adenocarcinoma
Malignant Female Reproductive System Neoplasm
Recurrent Cervical Carcinoma
Stage I Uterine Corpus Cancer AJCC v7
Stage I Vaginal Cancer AJCC v6 and v7
Stage IA Uterine Corpus Cancer AJCC v7
Stage IB Cervical Cancer AJCC v6 and v7
Stage IB Uterine Corpus Cancer AJCC v7
Stage IB2 Cervical Cancer AJCC v6 and v7

Interventions: Drug: Adavosertib
Drug: Cisplatin
Radiation: External Beam Radiation Therapy

First Posted Date: 2017-11-17

Last Posted Date: 2024-02-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT03345784

Locations: 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 5 locations

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2

Active, not recruiting

Conditions: Metastatic Triple Negative Breast Cancer

Interventions: Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
Drug: Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

First Posted Date: 2017-11-06

Last Posted Date: 2025-03-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 273

Registration Number: NCT03330847

Locations: 🇬🇧
Research Site, Southampton, United Kingdom

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

Phase 2

Active, not recruiting

Conditions: Locally Advanced Clear Cell Renal Cell Carcinoma
Metastatic Malignant Solid Neoplasm
Locally Advanced Malignant Solid Neoplasm
Stage IV Renal Cell Cancer AJCC v8
Metastatic Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8

Interventions: Drug: Adavosertib

First Posted Date: 2017-09-15

Last Posted Date: 2025-02-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT03284385

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States
🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States

and more 26 locations

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Phase 2

Completed

Conditions: Advanced Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm

Interventions: Drug: Adavosertib

First Posted Date: 2017-08-18

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT03253679

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States

and more 6 locations

WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

Phase 1

Completed

Conditions: Hypopharynx Squamous Cell Carcinoma
Oral Cavity Squamous Cell Carcinoma
Larynx Cancer

Interventions: Drug: AZD1775
Drug: Cisplatin
Radiation: Radiotherapy

First Posted Date: 2017-01-23

Last Posted Date: 2022-11-14

Lead Sponsor: University of Birmingham

Target Recruit Count: 9

Registration Number: NCT03028766

Locations: 🇬🇧
St. James' University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom
🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧
The Royal Marsden Hospital, London, United Kingdom

and more 3 locations

CISPLATIN + AZD-1775 In Breast Cancer

Phase 2

Completed

Conditions: Triple-negative Metastatic Breast Cancer

Interventions: Drug: Cisplatin
Drug: AZD1775

First Posted Date: 2017-01-06

Last Posted Date: 2021-11-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 34

Registration Number: NCT03012477

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Phase 2

Completed

Conditions: Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Interventions: Drug: AZD1775 and carboplatin (CBPT)
Drug: Durvalumab and Tremelimumab
Drug: AZD6738 and olaparib

First Posted Date: 2016-10-19

Last Posted Date: 2024-06-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 72

Registration Number: NCT02937818

Locations: 🇺🇦
Research Site, Sumy, Ukraine

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: AZD1775
Drug: Irinotecan

First Posted Date: 2016-09-19

Last Posted Date: 2020-10-12

Lead Sponsor: NYU Langone Health

Target Recruit Count: 7

Registration Number: NCT02906059

Locations: 🇺🇸
Laura and Isaac Perlmutter Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy